Eva V. Dubovsky: Distinguished Educator

Eva V. Dubovsky, professor with the UAB Health System in Birmingham, Ala., received the SNM Presidential Distinguished Educator Award during SNM's Annual Meeting. Dubovsky directed the society's Nuclear Medicine Board Review course for many years and has been active in resident and fellow education.


Dubovsky received her medical degree from Charles University, Prague, Czechoslovakia, where she served her internship and residency. She served her fellowships at Charles University and UAB. Her clinical interests include general nuclear medicine, renal nuclear medicine and renal transplantation nuclear medicine. She is certified by the American Board of Nuclear Medicine and has Czech certifications in nuclear medicine and as a nuclear medicine specialist.

She has served as secretary and treasurer of SNM and as president of the society's Southeastern Chapter. She is a member of the American Board of Nuclear Medicine and chair of the nuclear medicine RCC.

R. Edward Coleman Delivers Hal O. Anger Lecture

R. Edward Coleman, director of the nuclear medicine division at Duke University Medical Center in Durham, N.C., was invited to present the Hal O. Anger Memorial Lecture, sponsored by the Academic Council.

Coleman, who is also a professor of radiology and vice chair of the Department of Radiology at Duke University Medical Center, was recognized for his efforts in advancing molecular imaging and clinical applications of positron emission tomography (PET), PET/computed tomography (CT) and radionuclide therapy. Before joining Duke University Medical Center, he held academic appointments at Washington University School of Medicine in St. Louis and the University of Utah Medical Center in Salt Lake City.

Coleman's research has been centered on the role of PET scanning in lung cancer, prostate cancer and brain tumors. He was the nuclear medicine physician involved with the first PET scans when the scanner was first developed at the Mallinckrodt Institute of Radiology in the early 1970s. He has shown the utility of PET in several indications and worked on obtaining reimbursement for clinical PET procedures. He has studied the use of radiopharmaceuticals-such as Food and Drug Administration-approved agents, investigational new drug agents (monoclonal antibodies for diagnosis and therapy, I-131 MIBG for therapy of neuroendocrine tumors), Radioactive Drug Research Committee-approved agents (0-15 water for tumor blood flow, F-18 labeled agents for PET imaging of tumors, etc.) and fluorodeoxyglucose or FDG-and what they reveal about the body's metabolism. Coleman was also awarded this year's Georg Charles de Hevesy Nuclear Pioneer Award for his contributions to the nuclear medicine profession.

More Voices